BCGは製薬企業が人生を変える薬剤と治療を提供するというミッションを果たし、イノベーションを解き放って新薬を市場により速く上市するために新テクノロジー（デジタル、データ、アドバンスト・アナリティクスを含む）を活用できるよう支援します。
バイオ医薬品企業はインスピレーションをイノベーションに変え、生活を改善し生命を救う新薬を発見しています。そして、そのやり方の変革の真っ只中にいます。世界規模のパンデミックによりデジタル、データ&アナリティクスがこの業界の最前線で活用されるようになり、新薬の開発と患者への提供に要する時間が短縮されました。こうした次世代の組織能力により、生産とサプライチェーンの迅速化、効率化も進んでいます。次世代の組織能力は、より迅速で効率的な生産とサプライチェーンを推進するものです。また、ネットワークの迅速な再設計、新たなコマーシャル・モデルや患者参加型のベンチャーの創造、そしてM&Aを通じた新しい価値創造の機会の追求も可能にします。
Our biopharma consultants work closely BCG’s specialty businesses on specific value-chain priorities, including digital supply chain, next-generation sales, personalization, and digital marketing. With our guidance, companies can rapidly scale new capabilities and ways of working through agile at scale, data and digital platforms, and our Build-Operate-Transfer approach. We also collaborate with technologists, scientists, programmers, engineers, and human-centered designers from BCG X, our tech build and design unit.
As many herald a new “golden era” of medicine, one roadblock remains: the daunting complexity of conducting clinical trials. Syneos Health saw the enormous potential AI held when it came to accelerating the process. Baba Shetty, President of Technology & Data Solutions at Syneos Health, explains how BCG X helped them pave the way.
The company identified data-driven solutions that not only boost efficiency but can be converted into systemic change and scaled throughout the global business.
Production Network Transformation. We guided a biopharma company through a multiyear transformation of its client network, production system, and supply model. The transformation included realigning site roles, combining portfolios, and pruning SKUs. It resulted in overall savings of more than $1.5 billion.
Increased Customer Engagement. At a major pharma company, topline growth for a previously underperforming product jumped 50% in a year after BCG used CRM, payer data, and other analytics to assess its promotional efforts and improve customer engagement.
R&D Innovation Strategy. We worked with a biopharma company to develop a holistic cell and gene therapy strategy. By collaborating, we identified entry points, current capabilities, possible M&A options, and needed investments, and created a high-level business plan.
Disease Management Platform. BCG X partnered with a global pharmaceutical company to launch a platform for patients with inflammatory bowel disease, providing live daily data to clinicians and medical researchers, and allowing for better treatment and drug development.
Post-Merger Support. We provided post-merger support for the integration of two flagship biopharma companies, preserving the best of each entity’s operating models while unlocking new potential, and creating opportunities to scale and diversify the unified portfolio. The result increased value through improved stock performance.
Integrated into our biopharma industry solutions are an array of proprietary tools, including benchmarks, databases, and other knowledge assets. Some highlights:
The Disease Deep Dive Navigator data-mining tool provides up-to-date market intelligence on developments in seven therapy areas. Clients use dashboards to track activity by therapy, company, R&D pipeline, and clinical trials.
The Biopharma M&A Suite is a series of tools that clients can use to identify potential products or technologies that could be a good match for their current or future portfolio and capabilities.
The BCOMM Benchmark is a database of key metrics for European and US industry players that helps clients optimize their own commercial organizational structure and operating models. It includes organizational productivity ratios by geography and function, resource strength, and activity allocation by geography.
The External Supply Benchmark is a database of external supply metrics for outsourcing manufacturing operations to third-party suppliers, including data on corporate portfolio and performance, organization and operating models, and tech transfers. BCG hosts an annual companion event with top biopharma industry suppliers.
The Yield Optimization Tool Model compiles sensor and process data and then applies machine learning to predict and optimize biopharma manufacturing yield based on key drivers.
The Real-Time Demand Forecasting tool is part of the BCG Lighthouse high-frequency data and analytics platform. It uncovers rapid shifts in demand and source of demand, allowing for dynamic planning and resource allocation. Forecasts for trends come from sophisticated proprietary models and data visualization.
By leveraging innovative business models and partnerships, biopharma companies could reach patients in low- and middle-income countries at no extra cost.
Talking with Pfizer’s chief digital and technology officer about the extraordinary changes AI and other digital technologies are bringing to the health care industry.
The IRA provisions concerning the pricing of drugs for Medicare patients are creating new economic realities for health care players.
New GenAI offerings can benefit virtually every aspect of an organization, boosting efficiency and productivity in areas ranging from R&D to commercial activities.
Manufacturing costs are rising rapidly, with no end in sight. Leaders that balance the various tradeoffs can remain competitive over the long run.
Implementing GenAI is not easy in an industry with a complex value chain and intensive regulatory oversight. Companies will wrestle with both choice and complexity.
